Burns J W & Co. Inc. NY Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Burns J W & Co. Inc. NY lowered its holdings in Pfizer Inc. (NYSE:PFE) by 10.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 43,794 shares of the biopharmaceutical company’s stock after selling 4,860 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Pfizer were worth $1,267,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Olistico Wealth LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer during the second quarter worth about $29,000. Quarry LP acquired a new stake in shares of Pfizer during the second quarter worth about $31,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at about $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Thursday. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.24 on Friday, hitting $28.58. The company’s stock had a trading volume of 28,786,884 shares, compared to its average volume of 37,384,395. The stock has a 50 day moving average of $29.17 and a 200-day moving average of $28.31. The company has a market capitalization of $161.95 billion, a price-to-earnings ratio of -476.33, a price-to-earnings-growth ratio of 1.25 and a beta of 0.67. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $33.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.67 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.